Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

WATERS CORPORATION

Waters Corp. designs, manufactures, sells and services ultra performance liquid chromatography (UPLC), high performan... read more Featured Products: More products

Download Mobile App




Cell-Specific Bioorthogonal Tagging of Glycoproteins Developed

By LabMedica International staff writers
Posted on 31 Oct 2022

Altered glycoprotein expression is an undisputed corollary of cancer development. More...

Understanding these alterations is paramount but hampered by limitations underlying cellular model systems. For instance, the intricate interactions between tumor and host cannot be adequately recapitulated in monoculture of tumor-derived cell lines.

Cancer is a multifactorial disease consisting of an interplay between host and tumor. Posttranslational modifications (PTMs) heavily impact the plasticity of the proteome. Glycosylation is the most complex and most abundant PTM, but challenging to probe due to the non-templated nature of glycan biosynthesis.

Chemists and Biochemists at the Imperial College London (London, UK) have developed a new method to study the proteins released by cells, which could lead to the development of new tools to track diseases including cancer. Their method identifies proteins released by a specific type of cell, even if the cells are in a complex environment with many different cell types. The method is called Bio-Orthogonal Cell line-specific Tagging of Glycoproteins (BOCTAG).

The method uses bioorthogonal chemistry or click chemistry. The chemical tag is selected so that it "clicks" with another molecule that helps the scientists isolate the desired proteins or add a fluorescent tag to them. The investigators showed that BOCTAG worked in cell cultures with multiple cell lines and in mice, where they successfully tagged proteins from specific cancer cells. This method could also be used in fields such as immunology, infectious diseases, and to better understand disease biology, particularly how tumor cells change as a result of complex interactions in the body.

Cells are equipped by transfection with an artificial biosynthetic pathway that transforms bioorthogonally tagged sugars into the corresponding nucleotide-sugars. Only transfected cells incorporate bioorthogonal tags into glycoproteins in the presence of non-transfected cells. The team employed BOCTAG as an imaging technique and to annotate cell-specific glycosylation sites in mass spectrometry-glycoproteomics using Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS) equipped with a ACQUITY UPLC BEH Glycan (Waters Corporation, Milford, MA, USA). They demonstrated application in co-culture and mouse models, allowing for profiling of the glycoproteome as an important modulator of cellular function. The study was published on October 25 2022 in the journal Nature Communications.

Related Links:
Imperial College London
Waters Corporation


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Immunofluorescence Analyzer
IFA System
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.